---
schema_version: "secwatch.filing_event.v1"
accession: "0000318154-26-000003"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2026-02-03T23:59:59+00:00"
generated_at: "2026-05-16T05:27:12.788546+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amgen Q4 rev +9% to $9.9B; FY rev +10% to $36.8B; GAAP EPS $2.45, non-GAAP $21.84

## Summary
- Q4 total revenues $9.9B (+9% YoY); product sales +7% driven by 10% volume growth.
- GAAP EPS $2.45 Q4 (+111%), full year $14.23 (+88%); non-GAAP EPS full year $21.84 (+10%).
- Recorded $1.2B Otezla intangible impairment due to IRA Medicare price setting.
- Free cash flow $8.1B full year vs $10.4B prior, down on working capital timing.
- 18 products achieved record full-year sales; 14 exceeded $1B in annual sales.

## SEC filing metadata
- accession: 0000318154-26-000003
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2026-02-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000031815426000003/0000318154-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000031815426000003/amgn-20260203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000318154-26-000003
- JSON: https://secwatch.observer/filing/0000318154-26-000003.json
- Plain text: https://secwatch.observer/filing/0000318154-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.